SPRY |
ARS Pharmaceuticals, Inc. |
Aug 26, 2024 |
1 |
-$1.09M |
4 |
Aug 28, 2024 |
Director |
SPRY |
ARS Pharmaceuticals, Inc. |
Aug 21, 2024 |
4 |
-$11.5M |
4 |
Aug 23, 2024 |
Director |
KROS |
Keros Therapeutics, Inc. |
Aug 13, 2024 |
2 |
-$11M |
4 |
Aug 15, 2024 |
Director |
SCPH |
scPharmaceuticals Inc. |
Aug 13, 2024 |
2 |
$2M |
4 |
Aug 15, 2024 |
10%+ Owner |
TERN |
Terns Pharmaceuticals, Inc. |
Jul 15, 2024 |
6 |
-$562K |
4 |
Jul 17, 2024 |
Director, 10%+ Owner |
TELA |
TELA Bio, Inc. |
Jun 28, 2024 |
3 |
-$2.02M |
4 |
Jul 2, 2024 |
10%+ Owner |
IRON |
Disc Medicine, Inc. |
Jun 17, 2024 |
3 |
$3M |
4 |
Jun 20, 2024 |
Director |
ALPN |
ALPINE IMMUNE SCIENCES, INC. |
May 18, 2024 |
2 |
$0 |
4 |
May 20, 2024 |
Director |
ELVN |
Enliven Therapeutics, Inc. |
May 16, 2024 |
2 |
-$22.9M |
4 |
May 20, 2024 |
Director, 10%+ Owner |
CRVS |
Corvus Pharmaceuticals, Inc. |
May 6, 2024 |
2 |
$2.5M |
4 |
May 8, 2024 |
Director, 10%+ Owner |
NPCE |
NeuroPace Inc |
May 1, 2024 |
3 |
-$409K |
4 |
May 3, 2024 |
10%+ Owner |
NPCE |
NeuroPace Inc |
Apr 24, 2024 |
1 |
-$25K |
4 |
Apr 26, 2024 |
10%+ Owner |
NPCE |
NeuroPace Inc |
Apr 19, 2024 |
3 |
-$913K |
4 |
Apr 23, 2024 |
10%+ Owner |
NPCE |
NeuroPace Inc |
Apr 16, 2024 |
3 |
-$238K |
4 |
Apr 18, 2024 |
10%+ Owner |
NPCE |
NeuroPace Inc |
Apr 11, 2024 |
2 |
-$7.03M |
4 |
Apr 15, 2024 |
10%+ Owner |
KNTE |
Kinnate Biopharma Inc. |
Apr 3, 2024 |
5 |
$0 |
4 |
Apr 5, 2024 |
Director, 10%+ Owner |
TRAW |
Traws Pharma, Inc. |
Apr 1, 2024 |
0 |
$0 |
3/A |
Apr 12, 2024 |
Other* |
TRAW |
Onconova Therapeutics, Inc. |
Apr 1, 2024 |
0 |
$0 |
3 |
Apr 3, 2024 |
10%+ Owner |
QTTB |
Homology Medicines, Inc. |
Mar 25, 2024 |
0 |
$0 |
3 |
Mar 27, 2024 |
Director, 10%+ Owner |
THRX |
Theseus Pharmaceuticals, Inc. |
Feb 14, 2024 |
2 |
$0 |
4 |
Feb 14, 2024 |
Director, 10%+ Owner |
AVBP |
ArriVent Biopharma, Inc. |
Jan 30, 2024 |
10 |
$8M |
4 |
Jan 31, 2024 |
Director, 10%+ Owner |
ACET |
Adicet Bio, Inc. |
Jan 25, 2024 |
3 |
$7.5M |
4 |
Jan 26, 2024 |
Director, 10%+ Owner |
AVBP |
ArriVent Biopharma, Inc. |
Jan 25, 2024 |
0 |
$0 |
3 |
Jan 25, 2024 |
Director, 10%+ Owner |
EWTX |
Edgewise Therapeutics, Inc. |
Jan 23, 2024 |
1 |
$5M |
4 |
Jan 25, 2024 |
Director, 10%+ Owner |
ALPN |
ALPINE IMMUNE SCIENCES, INC. |
Jan 11, 2024 |
2 |
$1.85M |
4 |
Jan 16, 2024 |
Director |
ALPN |
ALPINE IMMUNE SCIENCES, INC. |
Dec 27, 2023 |
6 |
-$28.7M |
4 |
Dec 29, 2023 |
Director |
IRON |
Disc Medicine, Inc. |
Dec 18, 2023 |
3 |
-$36.6K |
4 |
Dec 20, 2023 |
Director |
IRON |
Disc Medicine, Inc. |
Dec 14, 2023 |
3 |
-$24.6M |
4 |
Dec 15, 2023 |
Director |
IRON |
Disc Medicine, Inc. |
Dec 12, 2023 |
8 |
-$7.9M |
4 |
Dec 14, 2023 |
Director |
PMVP |
PMV Pharmaceuticals, Inc. |
Nov 22, 2023 |
1 |
-$196K |
4 |
Nov 24, 2023 |
10%+ Owner |
NPCE |
NeuroPace Inc |
Oct 2, 2023 |
2 |
-$75.4K |
4 |
Oct 4, 2023 |
10%+ Owner |
SPRY |
ARS Pharmaceuticals, Inc. |
Aug 29, 2023 |
1 |
$3.1M |
4 |
Aug 31, 2023 |
Director |
GLTO |
Galecto, Inc. |
Aug 15, 2023 |
3 |
-$617K |
4 |
Aug 17, 2023 |
10%+ Owner |
IKNA |
Ikena Oncology, Inc. |
Aug 4, 2023 |
2 |
$0 |
4/A |
Sep 21, 2023 |
Director |
GLTO |
Galecto, Inc. |
Jul 31, 2023 |
3 |
-$628K |
4 |
Aug 2, 2023 |
10%+ Owner |
GLTO |
Galecto, Inc. |
Jul 25, 2023 |
3 |
-$114K |
4 |
Jul 27, 2023 |
10%+ Owner |
TSBX |
Turnstone Biologics Corp. |
Jul 20, 2023 |
6 |
$5M |
4 |
Jul 24, 2023 |
Director, 10%+ Owner |
TSBX |
Turnstone Biologics Corp. |
Jul 20, 2023 |
0 |
$0 |
3 |
Jul 20, 2023 |
Director, 10%+ Owner |
THRX |
Theseus Pharmaceuticals, Inc. |
Jul 17, 2023 |
2 |
$1.46M |
4 |
Jul 19, 2023 |
Director, 10%+ Owner |
GLTO |
Galecto, Inc. |
Jul 13, 2023 |
3 |
-$467K |
4 |
Jul 17, 2023 |
10%+ Owner |
ACET |
Adicet Bio, Inc. |
Jun 27, 2023 |
4 |
$1.83M |
4 |
Jun 29, 2023 |
Director, 10%+ Owner |
PASG |
Passage BIO, Inc. |
Jun 27, 2023 |
2 |
$1M |
4 |
Jun 29, 2023 |
10%+ Owner |
PRLD |
Prelude Therapeutics Inc |
May 22, 2023 |
1 |
$5M |
4 |
May 24, 2023 |
Director, 10%+ Owner |
ELVN |
Enliven Therapeutics, Inc. |
May 17, 2023 |
2 |
$9.1K |
4 |
May 19, 2023 |
Director, 10%+ Owner |
VRNA |
Verona Pharma plc |
May 11, 2023 |
4 |
-$9.94M |
4 |
May 15, 2023 |
Director |
KNTE |
Kinnate Biopharma Inc. |
May 4, 2023 |
5 |
$4.09M |
4 |
May 8, 2023 |
Director, 10%+ Owner |
KNTE |
Kinnate Biopharma Inc. |
Apr 28, 2023 |
9 |
$3.67M |
4 |
May 2, 2023 |
Director, 10%+ Owner |
TELA |
TELA Bio, Inc. |
Apr 19, 2023 |
3 |
-$1.79M |
4 |
Apr 21, 2023 |
10%+ Owner |
GLTO |
Galecto, Inc. |
Apr 13, 2023 |
9 |
-$128K |
4 |
Apr 17, 2023 |
10%+ Owner |
GLTO |
Galecto, Inc. |
Apr 10, 2023 |
9 |
-$121K |
4 |
Apr 12, 2023 |
10%+ Owner |
GLTO |
Galecto, Inc. |
Apr 5, 2023 |
6 |
-$222K |
4 |
Apr 7, 2023 |
10%+ Owner |
ELVN |
Enliven Therapeutics, Inc. |
Feb 23, 2023 |
2 |
$0 |
4 |
Feb 27, 2023 |
Director, 10%+ Owner |
KNTE |
Kinnate Biopharma Inc. |
Feb 17, 2023 |
2 |
$0 |
4 |
Feb 23, 2023 |
Director, 10%+ Owner |
IRON |
Disc Medicine, Inc. |
Feb 15, 2023 |
3 |
$2.5M |
4 |
Feb 17, 2023 |
Director, 10%+ Owner |
IRON |
Disc Medicine, Inc. |
Dec 29, 2022 |
4 |
$0 |
4 |
Jan 3, 2023 |
Director, 10%+ Owner |
IRON |
Disc Medicine, Inc. |
Dec 29, 2022 |
0 |
$0 |
3 |
Jan 3, 2023 |
Director, 10%+ Owner |
TERN |
Terns Pharmaceuticals, Inc. |
Dec 23, 2022 |
1 |
$1M |
4 |
Dec 28, 2022 |
Director, 10%+ Owner |
VRNA |
Verona Pharma plc |
Dec 22, 2022 |
5 |
-$136M |
4 |
Dec 27, 2022 |
Director |
SCPH |
scPharmaceuticals Inc. |
Nov 25, 2022 |
1 |
$4M |
4 |
Nov 29, 2022 |
10%+ Owner |
TCDA |
Tricida, Inc. |
Nov 22, 2022 |
3 |
-$2.21M |
4 |
Nov 25, 2022 |
Director, 10%+ Owner |
CMPX |
Compass Therapeutics, Inc. |
Nov 8, 2022 |
1 |
$1.29M |
4 |
Nov 10, 2022 |
Director, 10%+ Owner |
THRX |
Theseus Pharmaceuticals, Inc. |
Nov 7, 2022 |
1 |
$1M |
4 |
Nov 9, 2022 |
Director, 10%+ Owner |
THRD |
Third Harmonic Bio, Inc. |
Sep 19, 2022 |
5 |
$5.1M |
4 |
Sep 21, 2022 |
Director, 10%+ Owner |
EWTX |
Edgewise Therapeutics, Inc. |
Sep 16, 2022 |
1 |
$5M |
4 |
Sep 16, 2022 |
Director, 10%+ Owner |
THRD |
Third Harmonic Bio, Inc. |
Sep 14, 2022 |
0 |
$0 |
3 |
Sep 14, 2022 |
Director, 10%+ Owner |
SWTX |
SpringWorks Therapeutics, Inc. |
Sep 12, 2022 |
2 |
-$4.92M |
4 |
Sep 14, 2022 |
10%+ Owner |
TERN |
Terns Pharmaceuticals, Inc. |
Aug 16, 2022 |
6 |
$8.93M |
4 |
Aug 18, 2022 |
Director, 10%+ Owner |
XTNT |
Xtant Medical Holdings, Inc. |
Aug 15, 2022 |
2 |
$0 |
4 |
Aug 17, 2022 |
Director, 10%+ Owner |
SWTX |
SpringWorks Therapeutics, Inc. |
Aug 8, 2022 |
2 |
-$10.5M |
4 |
Aug 10, 2022 |
10%+ Owner |
SRRA |
Sierra Oncology, Inc. |
Jul 1, 2022 |
6 |
-$108M |
4 |
Jul 1, 2022 |
Director, 10%+ Owner |
ARQT |
Arcutis Biotherapeutics, Inc. |
Jun 24, 2022 |
2 |
-$7.29M |
4 |
Jun 28, 2022 |
10%+ Owner |
IKNA |
Ikena Oncology, Inc. |
Jun 22, 2022 |
4 |
-$1.13M |
4 |
Jun 24, 2022 |
Director |
PMVP |
PMV Pharmaceuticals, Inc. |
May 26, 2022 |
1 |
-$418K |
4 |
May 31, 2022 |
10%+ Owner |
EWTX |
Edgewise Therapeutics, Inc. |
May 18, 2022 |
1 |
$995K |
4 |
May 20, 2022 |
Director, 10%+ Owner |
CMPX |
Compass Therapeutics, Inc. |
May 11, 2022 |
3 |
$420K |
4 |
May 13, 2022 |
Director, 10%+ Owner |
CMPX |
Compass Therapeutics, Inc. |
May 6, 2022 |
3 |
$197K |
4 |
May 10, 2022 |
Director, 10%+ Owner |
PASG |
Passage BIO, Inc. |
May 3, 2022 |
2 |
$1.02M |
4 |
May 5, 2022 |
10%+ Owner |
ARQT |
Arcutis Biotherapeutics, Inc. |
Apr 6, 2022 |
6 |
-$18.2M |
4 |
Apr 8, 2022 |
10%+ Owner |
PMVP |
PMV Pharmaceuticals, Inc. |
Mar 29, 2022 |
3 |
-$10.3M |
4 |
Mar 31, 2022 |
10%+ Owner |
KNTE |
Kinnate Biopharma Inc. |
Feb 11, 2022 |
4 |
$1.99M |
4 |
Feb 15, 2022 |
Director |
SRRA |
Sierra Oncology, Inc. |
Jan 26, 2022 |
6 |
$6.43M |
4 |
Jan 28, 2022 |
Director, 10%+ Owner |
ETNB |
89bio, Inc. |
Jan 25, 2022 |
4 |
-$592K |
4 |
Jan 27, 2022 |
10%+ Owner |
PASG |
Passage BIO, Inc. |
Jan 20, 2022 |
1 |
$254K |
4/A |
May 5, 2022 |
10%+ Owner |
THRX |
Theseus Pharmaceuticals, Inc. |
Jan 19, 2022 |
3 |
$1.58M |
4 |
Jan 21, 2022 |
Director, 10%+ Owner |
PASG |
Passage BIO, Inc. |
Jan 14, 2022 |
3 |
$905K |
4 |
Jan 20, 2022 |
10%+ Owner |
PASG |
Passage BIO, Inc. |
Jan 11, 2022 |
3 |
$841K |
4 |
Jan 13, 2022 |
10%+ Owner |
THRX |
Theseus Pharmaceuticals, Inc. |
Jan 11, 2022 |
4 |
$443K |
4 |
Jan 13, 2022 |
Director, 10%+ Owner |
JANX |
Janux Therapeutics, Inc. |
Dec 29, 2021 |
2 |
-$820K |
4 |
Dec 30, 2021 |
Director |
JANX |
Janux Therapeutics, Inc. |
Dec 21, 2021 |
2 |
-$2.27M |
4 |
Dec 23, 2021 |
Director |
JANX |
Janux Therapeutics, Inc. |
Dec 16, 2021 |
2 |
-$7.5M |
4 |
Dec 17, 2021 |
Director |
ACET |
Adicet Bio, Inc. |
Dec 10, 2021 |
1 |
$3M |
4 |
Dec 14, 2021 |
Director, 10%+ Owner |
TCDA |
Tricida, Inc. |
Nov 15, 2021 |
2 |
$4M |
4 |
Nov 17, 2021 |
Director, 10%+ Owner |
CMPX |
Compass Therapeutics, Inc. |
Nov 4, 2021 |
2 |
$18.8M |
4 |
Nov 8, 2021 |
Director, 10%+ Owner |
THRX |
Theseus Pharmaceuticals, Inc. |
Oct 12, 2021 |
7 |
$10M |
4 |
Oct 14, 2021 |
Director, 10%+ Owner |
THRX |
Theseus Pharmaceuticals, Inc. |
Oct 6, 2021 |
0 |
$0 |
3 |
Oct 6, 2021 |
Director, 10%+ Owner |
CRVS |
Corvus Pharmaceuticals, Inc. |
Sep 20, 2021 |
1 |
-$6.76M |
4 |
Sep 22, 2021 |
Director, 10%+ Owner |
ALPN |
ALPINE IMMUNE SCIENCES, INC. |
Sep 17, 2021 |
2 |
$9.5M |
4 |
Sep 21, 2021 |
Director, 10%+ Owner |
RPTX |
Repare Therapeutics Inc. |
Sep 3, 2021 |
4 |
-$275K |
4 |
Sep 8, 2021 |
Director |
RPTX |
Repare Therapeutics Inc. |
Aug 31, 2021 |
6 |
-$1.29M |
4 |
Sep 2, 2021 |
Director |
RPTX |
Repare Therapeutics Inc. |
Aug 26, 2021 |
6 |
-$616K |
4 |
Aug 30, 2021 |
Director |
RPTX |
Repare Therapeutics Inc. |
Aug 23, 2021 |
6 |
-$622K |
4 |
Aug 25, 2021 |
Director |
RPTX |
Repare Therapeutics Inc. |
Aug 17, 2021 |
4 |
-$693K |
4 |
Aug 19, 2021 |
Director |
XTNT |
Xtant Medical Holdings, Inc. |
Aug 15, 2021 |
2 |
$0 |
4 |
Aug 17, 2021 |
Director, 10%+ Owner |
AFIB |
Acutus Medical, Inc. |
Jul 19, 2021 |
2 |
$15M |
4 |
Jul 21, 2021 |
Director, 10%+ Owner |
ELVN |
IMARA Inc. |
Jul 16, 2021 |
1 |
$10M |
4/A |
Jul 23, 2021 |
Director, 10%+ Owner |
SWTX |
SpringWorks Therapeutics, Inc. |
Jul 1, 2021 |
1 |
-$1.36M |
4 |
Jul 6, 2021 |
10%+ Owner |
SWTX |
SpringWorks Therapeutics, Inc. |
Jun 28, 2021 |
1 |
-$554K |
4 |
Jun 30, 2021 |
10%+ Owner |
SWTX |
SpringWorks Therapeutics, Inc. |
Jun 23, 2021 |
3 |
-$4.82M |
4 |
Jun 25, 2021 |
10%+ Owner |
JANX |
Janux Therapeutics, Inc. |
Jun 15, 2021 |
8 |
$12M |
4 |
Jun 16, 2021 |
Director |
SWTX |
SpringWorks Therapeutics, Inc. |
Jun 10, 2021 |
1 |
-$2.63M |
4 |
Jun 14, 2021 |
10%+ Owner |
JANX |
Janux Therapeutics, Inc. |
Jun 10, 2021 |
0 |
$0 |
3 |
Jun 10, 2021 |
Director |
SWTX |
SpringWorks Therapeutics, Inc. |
Jun 7, 2021 |
3 |
-$4.1M |
4 |
Jun 9, 2021 |
10%+ Owner |